The data obtained also revealed a favorable prognosis of Piezo2 expression mainly in ER-positive or HER2-negative breast cancer, but a poor prognosis in patients with low expression of Piezo2, suggesting that low expression of Piezo2 might be a potential prognostic biomarker in breast cancer. Here, PIEZO2 is linked to breast cancer.